ArticleFrontiers in neurology
Comorbidities and impact on quality of life in patients with Ménière's disease: a single-center cross-sectional study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ménière's disease (MD) is a chronic vestibular disorder that significantly impacts patients' quality of life (QoL). However, the influence of comorbid conditions on QoL in MD patients remains inadequately explored. Objective: To investigate the prevalence of comorbidities in patients with MD and analyze their impact on patients' QoL. Methods: A cross-sectional analysis was conducted on 473 MD patients who received treatment in our hospital. Demographic data, comorbidity information, psychological symptoms (assessed by Hospital Anxiety and Depression Scale, HAD) and QoL (evaluated by Ménière's disease Quality of Life Questionnaire, MDoQ) were collected. Spearman correlation analysis was used to explore the relationship between comorbidities and QoL scores, and independent-samples t-test was applied for intergroup comparison. A multiple linear regression analysis was conducted to identify comorbidities influencing MDoQ. Results: The study included 328 females (69.3%) and 145 males (30.7%) with a mean age of 45.6 ± 14.5 years and an average disease duration of 4.5 ± 2.0 years. The most common comorbidities were hypertension (49.0%), sleep disorders (36.6%), and diabetes mellitus (28.8%). Clear anxiety symptoms were observed in 59.2% of subjects, whereas distinct depressive symptoms were detected in 53.9%. The mean MDoQ score was 43.62 ± 12.50 (range: 25-76). Correlation analysis revealed that hypertension ( Conclusion: Comorbidities are highly prevalent in MD patients, with hypertension, sleep disorders and diabetes mellitus being the most common. These comorbidities, together with the high incidence of anxiety and depression, significantly impair patients' QoL. Comprehensive management of MD should include systematic screening, early intervention for common comorbidities and psychological support to improve patients' clinical outcomes and QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.